Bone Cancer News

Bone Cancer News

Ganitumab Provides No Benefit in Metastatic Ewing Sarcoma

Publish Date February 1, 2023

Adding ganitumab to standard chemotherapy does not provide a benefit for patients with metastatic Ewing sarcoma, a phase 3 trial suggests.

Childhood, Adolescent Cancers Linked to Higher Risk of Major Psychiatric Disorders

Publish Date January 25, 2023

Compared with the general population, survivors of childhood and adolescent cancers have an increased risk of 6 major psychiatric disorders.

Treatment Changes May Have Reduced Rates of Invasive Breast Cancer in Childhood Cancer Survivors

Publish Date October 19, 2022

The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.

Adding Ifosfamide to MAP Provides No Benefit in High-Grade Osteosarcoma

Publish Date September 28, 2022

Phase 3 data do not support adding ifosfamide to adjuvant methotrexate, doxorubicin, and cisplatin in patients with high-grade osteosarcoma.

Dinutuximab Plus GM-CSF Falls Short in Recurrent Osteosarcoma

Publish Date July 14, 2022

Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.

Carboplatin Deemed Acceptable Replacement for Actinomycin-D in Ewing Sarcoma

Publish Date July 12, 2022

There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.

Standardized Treatment Eliminates Outcome Disparities in Non-Metastatic Osteosarcoma

Publish Date June 7, 2022

Survival outcomes for patients on the EURAMOS-1 trial were not affected by race/ethnicity or poverty exposure.

High-Dose Ifosfamide Bests Topotecan-Cyclophosphamide in Relapsed/Refractory Ewing Sarcoma

Publish Date June 6, 2022

Ifosfamide improved event-free and overall survival.

Persistent Opioid Use After Sarcoma Treatment Explored Among Youth

Publish Date May 27, 2022

Twenty-three percent of adolescents and young adults with sarcoma who used opioids during treatment had new persistent opioid use after treatment.

Lurbinectedin Deemed “Valuable” Treatment Option for Relapsed Ewing Sarcoma

Publish Date May 19, 2022

Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.

Intensification Does Not Improve Survival in Metastatic Ewing Sarcoma

Publish Date May 18, 2022

High-dose treosulfan plus melphalan followed by autologous stem cell reinfusion did not improve event-free or overall survival.

No PFS Benefit With Carotuximab in Advanced Angiosarcoma

Publish Date April 18, 2022

Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.

Patients With Axial Osteosarcoma May Have Higher Risk for Local Recurrence

Publish Date April 14, 2022

Patient age and tumor site were linked to the risk of local recurrence, and histological response to neoadjuvant chemotherapy was tied to the risk of new metastatic disease.

Irinotecan-Temozolomide “Effective and Safe” for Relapsed Ewing Sarcoma

Publish Date April 13, 2022

In a pooled analysis of 6 studies, 44% of patients responded to combination irinotecan and temozolomide.

Phthalates in Medications May Increase Risk of Childhood Cancers

Publish Date March 25, 2022

Children prescribed a medication containing a phthalate had a 19% higher risk of developing any childhood cancer.

Osteosarcoma Incidence Highest in Black Patients

Publish Date March 16, 2022

Black individuals had the highest incidence of osteosarcoma, but the worst survival was seen in American Indian/Alaska Native individuals.

Denosumab May Increase Risk of Local Recurrence in Giant Cell Tumor of the Bone

Publish Date March 15, 2022

Researchers compared patients with giant cell tumor of the bone who were treated with surgery alone or surgery plus preoperative denosumab.

Bone Cancer Survivors Are at Increased Risk of Neurocognitive Difficulties

Publish Date February 23, 2022

Researchers sought to measure the risk of long-term neurocognitive outcomes in survivors of osteosarcoma and Ewing sarcoma.

Tool Predicts Cancer-Specific Survival in Primary Long Bone Osteosarcoma

Publish Date February 22, 2022

Researchers describe the development and validation of a risk-stratification system that uses clinicopathologic factors not included in a traditional TNM staging system.

No Benefit Seen With Longer Antibiotic Course After Surgery for Bone Tumors

Publish Date January 14, 2022

There were no significant differences between the treatment groups in rates of surgical site infections, unplanned operations, oncologic events, or all-cause mortality.